Alopecia
Drug research and approvals for alopecia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 91 studies of alopecia are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 91
- Trials authorized in Canada: 26
- FDA orphan approvals: 0
- EU medicines: 1
- Efficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative StudyNCT07947992 · Not applicable · Sohag University · starts Oct 29, 2026
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local…NCT07926711 · Phase 4 · Dow University of Health Sciences · starts Jan 1, 2026
- Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic AlopeciaNCT07907783 · Phase 2 · Pelage Pharmaceuticals, Inc. · starts Nov 10, 2026
- Phase 2/3 Efficacy and Safety of PP405 in Adult MalesNCT07819435 · Phase 2 / Phase 3 · Pelage Pharmaceuticals, Inc. · starts Sep 21, 2026
- Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light TherapyNCT07810504 · Not applicable · K. Kay Durairaj, MD, FACS, A Medical Corporation · starts Mar 17, 2026
- Efficacy and Safety of Two Hair Supplements in Men With Androgenic AlopeciaNCT07806474 · Not applicable · Activ'inside · starts Oct 5, 2026
- UV-Trichoscopic Red Fluorescence in Alopecia AreataNCT07803874 · Not reported · Istanbul Training and Research Hospital · starts Jul 1, 2026
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataNCT07772492 · Phase 3 · AbbVie · starts Aug 24, 2026
Approved 2
- MinoxidilSulfonylurea receptor 2, Kir6.2 opener
- FinasterideSteroid 5-alpha-reductase 2 inhibitor
Phase 3 2
- DutasterideSteroid 5-alpha-reductase inhibitor
- ClascoteroneAndrogen Receptor antagonist
Phase 2 12 of 16
- BimatoprostProstanoid FP receptor agonist
- Dalosirvat
- EdoxabanCoagulation factor X inhibitor
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- EfalizumabIntegrin alpha-L/beta-2 (LFA-1) inhibitor
- RitlecitinibTyrosine-protein kinase JAK3 inhibitor
- CetirizineHistamine H1 receptor antagonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- SetipiprantG protein-coupled receptor 44 antagonist
- BrepocitinibTyrosine-protein kinase TYK2 inhibitor
Phase 1 or earlier 4
- TacrolimusFK506-binding protein 1A inhibitor
- Zinc ion
- PaliferminFibroblast growth factor receptor 2 agonist
- GabapentinVoltage-gated calcium channel modulator
How its trials ended
533 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 98 whose ending is known, 43% met their primary endpoint, 4% missed it and 53% stopped early.
- Completed, result not reported21941%
- Ongoing13425%
- Status unknown8215%
- Met its primary endpoint428%
- Stopped: other or unclear326%
- Stopped: enrollment or feasibility102%
- Stopped: sponsor or business decision61%
- Missed its primary endpoint41%
- Stopped: lack of efficacy41%
| Sep 15, 2026 | A randomized, double-blind, single-center, vehicle-controlled, phase 1 study to assess safety and effects of PP405 on follicular unit activity in adult males…PP405 | Pelage Pharmaceuticals | Ongoing |
| Sep 15, 2026 | A randomized, multicenter, double-blind, vehicle-controlled, phase 2/3 study to assess efficacy and long-term safety of PP405 in adult males with androgenetic…PP405 | Pelage Pharmaceuticals | Pending |
| Apr 15, 2026 | A phase 2, randomized, multicenter, double-blind, placebo-controlled proof of concept study to investigate efficacy and safety of LY4005130 in adult…LY4005130 | Eli Lilly | Ongoing |
| Dec 16, 2025 | A phase 1, open-label, maximal use trial to assess the pharmacokinetics, safety, and tolerability of PP405 topical gel 0.05% in adult participants with…PP405 | Pelage Pharmaceuticals | Closed |
| Aug 15, 2025 | A double-blind, randomized, placebo-controlled multicenter study to evaluate the efficacy and safety of deuruxolitinib in adolescent patients with severe…Deuruxolitinib (CTP-543) | Sun Pharmaceutical Industries | Ongoing |
| Jun 25, 2025 | A phase 3 randomized, double-blind, placebo-controlled study to investigatethe efficacy and safety of ritlecitinib in pediatric participants 6 to less than 12…Ritlecitinib (PF-06651600) | Pfizer | Closed |
| Jun 13, 2025 | A phase 2a, randomized, double-blind, placebi-controlled, proof-of-concept trial with part b open-label extension of ADX-914 for the treatment of severe…ADX-914 | Q32 Bio Inc | Ongoing |
| Jan 10, 2025 | A phase 1b/2a, intraindividual study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ALD-102 solution for intradermal…ALD-102 | Aldena Therapeutics (Uk), Ltd. | Ongoing |
| May 8, 2024 | A phase 2, randomized, double-blind, placebo-controlled, parallel group, 3- arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy…Amlitelimab (SAR445229) | Sanofi-Aventis Canada Inc | Closed |
| Jan 30, 2024 | A phase 2b, randomized, double-blind, parallel group, placebo-controlled 60- week study to evaluate the efficacy and safety of rezpegaldesleukin in treatment…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Ongoing |
| Dec 21, 2017 | Trafermin in combination with plasma and platelet rich…Treatment of alopecia areata in pediatric patients | HCell, Inc. | Designated |
| Jun 13, 2003 | DiphenylcyclopenoneTreatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU]) | Lloyd E. King, Jr. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 15, 2023 | LitfuloRitlecitinib | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA